The GlaxoSmithKline and Merck Group-backed digital fertility platform has raised $14.7m, a year after it was formed by the merger of Auxogyn and Fertility Authority.
Progyny, a US-based digital healthcare technology producer backed by pharmaceutical firms GlaxoSmithKline and Merck Group, has raised $14.7m in series B funding from undisclosed investors.
Formed in April 2015 through the merger of reproductive health technology providers Auxogyn and Fertility Authority, Progyny’s core product is a digital fertility platform that can shorten the time it takes to get pregnant and cut fertility-related costs.
The company will spend the funding on expanding the features and clinical tools available for its…
